IKS applies laboratory expertise to motorcycling
Sets up racing team and uses XiltriX to monitor racing performance of rider Mervyn Verploegen
According to IKS md Stephen Tierney, this is not just the usual sponsorship arrangement: IKS will be applying the expertise accumulated in more than 20 years of laboratory monitoring to improve racing performance.
‘We’re delighted to be able to help this young talent advance his sporting career and to support his family, who are very much involved,’ he said. ‘Unusually in such situations, though, we can also contribute technically by applying the technology employed in our XiltriX laboratory monitoring systems to measuring parameters such as tyre temperature and pressure that have a significant impact on racing performance.’
He added: ‘Motor racing is pure adrenaline, but control is vital: our traditional markets are rather more conservative and sometimes slow moving, but control is every bit as important. We like to think that being involved in two such different environments will help develop the progressive and innovative philosophy that will drive our company forward.’
IKS International, based in Rosmalen, near 's-Hertogenbosch, supplies advanced products and services to clinical, biotechnology, pharmaceutical and microbiology laboratories worldwide.
You may also like
Regulatory
MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results
The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
Manufacturing
Roquette opens pharmaceutical innovation centre in Brazil
The Health & Pharma Solutions facility in São Paolo offers state-of-the-art laboratories for customers, with the Northeast Center for Strategic Technologies partnering with Roquette to empower young women to pursue careers in science through the Futuras Cientistas programme at the facility
Manufacturing
Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours
The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio